Hepatic sinusoidal obstruction syndrome after immune-checkpoint-inhibitor therapy: when the liver sends SOS.
| Autor: | Kasper P; Department of Gastroenterology and Hepatology, University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany philipp.kasper@uk-koeln.de., Fischer AK; Department of Pathology, University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany., Schumacher JC; Department of Gastroenterology and Hepatology, University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ case reports [BMJ Case Rep] 2024 Sep 30; Vol. 17 (9). Date of Electronic Publication: 2024 Sep 30. |
| DOI: | 10.1136/bcr-2024-260066 |
| Abstrakt: | A woman in her 50s presented to the hospital with new-onset jaundice and ascites. Her medical history included a melanoma of the right shoulder, diagnosed 8 months before, for which she had received four cycles of ipilimumab and nivolumab. Due to the oncological history and previous immunotherapy, an immune-checkpoint-inhibitor (ICI)-induced hepatitis was suspected, and a high-dose corticosteroid treatment was initiated. However, as there was no improvement in the liver function tests, a percutaneous liver biopsy was performed for further diagnostic clarification. Histological analysis ultimately identified a hepatic sinusoidal obstruction syndrome (SOS) as the underlying cause of liver dysfunction and portal hypertension. ICI-related hepatic SOS represents an extremely rare adverse event related to immunotherapy that should be considered in all patients with treatment-refractory ICI-related hepatotoxicity and clinical signs of portal hypertension. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|